Carvykti

Carvykti is a medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) and has not responded to treatment (refractory). It is used in adults who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, whose disease has worsened since the last treatment, and for whom treatment with lenalidomide did not work (refractory). Multiple myeloma is rare, and Carvykti was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 28 February 2020. Further information on the orphan designation can be found in the [orphan designation page](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2252). Carvykti contains the active substance ciltacabtagene autoleucel, consisting of genetically modified T cells (a type of white blood cells).